CFM-2 is a potent, selective, non-competitive AMPA receptor antagonist with anticonvulsant activity in various seizure animal models; it inhibits the extracellular signal-regulated kinase (ERK1/2) pathway, reduces phosphorylation of cAMP-responsive element-binding protein (CREB), suppresses cyclin D1 expression, upregulates cell cycle regulators and tumor suppressor proteins p21 and p53, and decreases the number of lung adenocarcinoma cells in G2 and S phases of the cell cycle; it delays seizure progression in pentylenetetrazole-kindled animals and antagonizes the long-term increase in sensitivity to convulsant effects of GABA function inhibitors; intrathecal administration of CFM-2 significantly attenuates mechanical and thermal hypersensitivities in the ipsilateral hind paw in a CFA-induced inflammatory pain model.